The PATCH trial: efficacy and safety of 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a study protocol for a multicentric, double-blind, enriched enrolment randomised withdrawal, vehicle-controlled study

Chunmei Zhao, Niti Shrestha, Hongbing Liu, Ying Shen, Lan Meng, Bifa Fan, Fang Luo, Chunmei Zhao, Niti Shrestha, Hongbing Liu, Ying Shen, Lan Meng, Bifa Fan, Fang Luo

Abstract

Introduction: Trigeminal neuralgia (TN) is characterised by a sudden, severe, electric shock like paroxysmal pain, which is almost always associated with triggers. Carbamazepine is the first-line medical management of TN. However, side effects are common. Currently, there is no ideal treatment for TN. Since there is a known abnormality of Na+ channels in the trigger zone, 5% lidocaine-medicated plaster (LMP), which can block the Na+ channels on Aδ and C fibres, is an effective treatment method in many chronic pain conditions. A case report has found the benefit of LMP for the treatment of TN without any side effects. Whether LMP is an option for the treatment of TN is worth exploring.

Methods and analysis: The PATCH trial is a double-blind, enriched enrolment with randomised withdrawal, vehicle-controlled trial, aiming to explore the effects and safety of LMP in patients with TN. There is a 3-week initial open-label phase, followed by a 4-week double-blind treatment phase for responders. In the double-blind phase, patients will have to withdraw from this PATCH study if they meet one of the following criteria for treatment failure such as: >50% increase in pain intensity or paroxysms, lack of efficacy or side effects. The primary outcome will be the number of treatment failures. Adverse events will also be monitored throughout the study.

Ethics and dissemination: This study protocol has been approved by the Institutional Review Board of Beijing Tiantan Hospital (approval number: KY 2020-102-02). The results will be disseminated in international academic meetings and published in peer-reviewed journals.

Trial registration number: NCT04570293.

Keywords: neurological pain; neuropathology; pain management.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the study procedure. LMP, 5% lidocaine-medicated plaster.

References

    1. Headache Classification Committee of the International Headache Society (IHS) . The international classification of headache disorders, 3rd edn. Cephalalgia 2018;38:1–211.
    1. Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol 2013;13:292–307. 10.1136/practneurol-2013-000536
    1. Rappaport HZ, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56:127–38. 10.1016/0304-3959(94)90086-8
    1. Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. J Neurosurg 2002;96:532–43. 10.3171/jns.2002.96.3.0532
    1. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain 2002;18:4–13. 10.1097/00002508-200201000-00002
    1. Liu M, Zhong J. Mechanism underlying cranial nerve rhizopathy. Med Hypotheses 2020;142:109801. 10.1016/j.mehy.2020.109801
    1. Liu J, Dai J, Lingling E, et al. . Trigeminal neuralgia may be caused by abnormality of the trigger zone. Med Hypotheses 2010;74:818–9. 10.1016/j.mehy.2009.12.007
    1. Bendtsen L, Zakrzewska JM, Heinskou TB, et al. . Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol 2020;19:784–96. 10.1016/S1474-4422(20)30233-7
    1. Wiffen PJ, Derry S, Moore RA, et al. . Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4:CD005451. 10.1002/14651858.CD005451.pub3
    1. Tentolouris-Piperas V, Lee G, Reading J, et al. . Adverse effects of anti-epileptics in trigeminal neuralgiform pain. Acta Neurol Scand 2018;137:566–74. 10.1111/ane.12901
    1. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984;15:240–4. 10.1002/ana.410150306
    1. Lechin F, van der Dijs B, Amat J, et al. . Definite and sustained improvement with pimozide of two patients with severe trigeminal neuralgia. Some neurochemical, neurophysiological and neuroendocrinological findings. J Med 1988;19:243–56.
    1. Moore D, Chong MS, Shetty A, et al. . A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth 2019;123:e385–96. 10.1016/j.bja.2019.05.026
    1. Bischoff JM, Petersen M, Uçeyler N, et al. . Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. Anesthesiology 2013;119:1444–52. 10.1097/ALN.0b013e3182a2a243
    1. Binder A, Bruxelle J, Rogers P, et al. . Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393–408. 10.2165/00044011-200929060-00003
    1. Cheville AL, Sloan JA, Northfelt DW, et al. . Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer 2009;17:451–60. 10.1007/s00520-008-0542-x
    1. Krumova EK, Zeller M, Westermann A, et al. . Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. Pain 2012;153:273–80. 10.1016/j.pain.2011.08.020
    1. Bursi R, Piana C, Grevel J, et al. . Evaluation of the population pharmacokinetic properties of lidocaine and its metabolites after long-term multiple applications of a lidocaine plaster in post-herpetic neuralgia patients. Eur J Drug Metab Pharmacokinet 2017;42:801–14. 10.1007/s13318-017-0400-7
    1. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111–7. 10.1177/0091270002239817
    1. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111–7. 10.1177/0091270002239817
    1. Fleming JA, O’Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381–8. 10.1155/2009/723179
    1. Burch F, Codding C, Patel N, et al. . Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253–5. 10.1016/j.joca.2003.10.007
    1. Hans G, Joukes E, Verhulst J, et al. . Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. Curr Med Res Opin 2009;25:2737–43. 10.1185/03007990903282297
    1. Madsen CS, Johnsen B, Fuglsang-Frederiksen A, et al. . Differential effects of a 5% lidocaine medicated patch in peripheral nerve injury. Muscle Nerve 2013;48:265–71. 10.1002/mus.23794
    1. Meier T, Wasner G, Faust M, et al. . Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151–8. 10.1016/S0304-3959(03)00317-8
    1. Meier T, Faust M, Hüppe M, et al. . [Reduction of chronic pain for non-postherpetic peripheral neuropathies after topical treatment with a lidocaine patch]. Schmerz 2004;18:172–8. 10.1007/s00482-003-0272-4
    1. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26:1607–19. 10.1185/03007995.2010.483675
    1. Tamburin S, Schweiger V, Magrinelli F, et al. . Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia. Ann Pharmacother 2014;48:1521–4. 10.1177/1060028014544166
    1. Moore A, Derry S, Eccleston C, et al. . Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. 10.1136/bmj.f2690
    1. McQuay HJ, Derry S, Moore AR, et al. . Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008;135:217–20. 10.1016/j.pain.2008.01.014
    1. Toth C, Mawani S, Brady S, et al. . An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012;153:2073–82. 10.1016/j.pain.2012.06.024
    1. Huffman CL, Goldenberg JN, Weintraub J, et al. . Efficacy and safety of once-daily controlled-release pregabalin for the treatment of patients with postherpetic neuralgia: a double-blind, enriched enrollment randomized withdrawal, placebo-controlled trial. Clin J Pain 2017;33:569–78. 10.1097/AJP.0000000000000445
    1. Zakrzewska JM, Palmer J, Morisset V, et al. . Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2A trial. Lancet Neurol 2017;16:291–300. 10.1016/S1474-4422(17)30005-4
    1. Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 2005;116:322–31. 10.1016/j.pain.2005.05.001
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap 1994;23:129–38.
    1. Buysse DJ, Reynolds CF, Monk TH, et al. . The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213. 10.1016/0165-1781(89)90047-4
    1. Brazier JE, Harper R, Jones NM, et al. . Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160–4. 10.1136/bmj.305.6846.160
    1. Martini A, Del Balzo G, Schweiger V, et al. . Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. Minerva Med 2018;109:344–51. 10.23736/S0026-4806.18.05690-2
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Moher D, Hopewell S, Schulz KF, et al. . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. 10.1136/bmj.c869
    1. Issue information-declaration of Helsinki. J Bone Miner Res 2019;34. 10.1002/jbmr.3486
    1. Campbell BJ, Rowbotham M, Davies PS, et al. . Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343–50. 10.1002/jps.10133
    1. Campbell BJ, Rowbotham M, Davies PS, et al. . Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343–50. 10.1002/jps.10133

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa